Amgen (AMGN) Amortization - Intangibles (2009 - 2012)
Amgen (AMGN) posted quarterly Amortization - Intangibles of $73.0 million for Q4 2012, little changed year-over-year from $73.0 million in Q1 2012, and down 1.35% on a QoQ basis from $74.0 million in Q3 2012.
Amgen (AMGN) Amortization - Intangibles (2009 - 2012) Analysis & Trends
Amgen (AMGN) has reported Amortization - Intangibles for 4 consecutive years, with $73.0 million the latest figure, recorded in Q4 2012.
- In Q4 2012, Amortization - Intangibles changed 0.0% year-over-year to $73.0 million; the TTM figure through Dec 2012 stood at $294.0 million (changed 0.0% YoY), while the FY2012 annual figure was $294.0 million, changed 0.0% from the prior year.
- Amortization - Intangibles came in at $73.0 million for Q4 2012 at Amgen, down from $74.0 million in the prior quarter.
- The five-year high for Amortization - Intangibles was $74.0 million in Q1 2009, with the low at $73.0 million in Q2 2009.
- Average Amortization - Intangibles over 4 years is $73.5 million, with a median of $73.5 million recorded in 2009.
- The largest YoY upside for Amortization - Intangibles was 0.0% in 2010 against a maximum downside of 0.0% in 2010.
- Year by year, Amortization - Intangibles stood at $73.0 million in 2009, then changed by 0.0% to $73.0 million in 2010, then changed by 0.0% to $73.0 million in 2011, then changed by 0.0% to $73.0 million in 2012.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $73.0 million, $74.0 million, and $73.0 million for Q4 2012, Q3 2012, and Q2 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 73.00 Mn |
| Sep 30, 2012 | 74.00 Mn |
| Jun 30, 2012 | 73.00 Mn |
| Mar 31, 2012 | 74.00 Mn |
| Dec 31, 2011 | 73.00 Mn |
| Sep 30, 2011 | 74.00 Mn |
| Jun 30, 2011 | 73.00 Mn |
| Mar 31, 2011 | 74.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 74.00 Mn |
| Jun 30, 2010 | 73.00 Mn |
| Mar 31, 2010 | 74.00 Mn |
| Dec 31, 2009 | 73.00 Mn |
| Sep 30, 2009 | 74.00 Mn |
| Jun 30, 2009 | 73.00 Mn |
| Mar 31, 2009 | 74.00 Mn |